Table 2.
Predictors of death in the first 36 months after ART initiation (Cox models)
| Variables | Number of deaths | Multivariable model | |
|---|---|---|---|
| HR (95% CI) | P-value | ||
| Age at ART initiation (years) | <0.0001 | ||
| 16–29 | 613 | 1 | |
| 30–39 | 1,182 | 0.93 (0.84–1.03) | |
| 40–49 | 872 | 1.02 (0.91–1.13) | |
| 50–59 | 402 | 1.31 (1.15–1.49) | |
| ≥60 | 120 | 1.66 (1.36–2.03) | |
| Gender | <0.0001 | ||
| Female | 1,822 | 1 | |
| Male | 1,367 | 1.41 (1.30–1.52) | |
| Year of ART initiation | <0.0001 | ||
| <2007 | 1,096 | 1 | |
| 2007–2010 | 1,346 | 1.37 (1.25–1.51) | |
| 2011 and after | 747 | 1.79 (1.61–1.99) | |
| Initial clinical stage | <0.0001 | ||
| A, B/I, II | 643 | 1 | |
| AIDS/III, IV | 1,495 | 1.91 (1.74–2.11) | |
| Missing | 1,051 | 1.63 (1.46–1.81) | |
| Initial CD4 cell count (cells/µL) | <0.0001 | ||
| ≥350 | 120 | 1 | |
| 200–349 | 400 | 1.63 (1.33–2.00) | |
| 100–199 | 610 | 2.37 (1.94–2.89) | |
| 50–99 | 493 | 3.36 (2.74–4.12) | |
| 0–49 | 1,053 | 5.02 (4.14–6.09) | |
| Missing | 513 | 2.92 (2.38–3.59) | |
| Initial hemoglobin (g/dL) | <0.0001 | ||
| ≥12 | 241 | 1 | |
| 10–12 | 559 | 1.30 (1.12–1.52) | |
| 7.5–10 | 864 | 2.14 (1.84–2.48) | |
| <7.5 | 408 | 3.80 (3.21–4.49) | |
| Missing | 1,117 | 0.76 (0.65–0.88) | |
| First ART regimen | 0.0010 | ||
| AZT+3TC/FTC+NVP/EFV | 815 | 1 | |
| D4T+3TC/FTC+NVP/EFV | 903 | 1.20 (1.08–1.33) | |
| TDF+3TC/FTC+NVP/EFV | 723 | 1.16 (1.04–1.29) | |
| Others/unknown | 748 | 1.03 (0.93–1.15) | |
| BMI (kg/m2) | <0.0001 | ||
| 18–25 | 767 | 1 | |
| <18 | 781 | 2.06(1.86–2.29) | |
| ≥25 | 102 | 0.64 (0.52–0.79) | |
| Missing | 1,539 | 1.82 (1.64–2.02) | |
| Total number of patients started ART in 2014–2015 and still in care, in the facility | <0.0001 | ||
| <500 | 747 | 1 | |
| 500–1,000 | 1,620 | 1.20 (1.09–1.32) | |
| ≥1,000 | 822 | 0.86 (0.77–0.97) | |
Abbreviations: ART, antiretroviral therapy; BMI, body mass index.